Bayer AG NA (0P6S)
London Exchange · UK · prices in EUR · close of 21 Oct 2026
Key indicators
| Last close | EUR 44.77 |
|---|---|
| 52-week range | 25.71 – 54.00 |
| Return, 1 month / 3 months | −9.4% / −3.2% |
| Return, 1 year / 3 years | +67.4% / +4.2% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 45 |
| Volatility (1 year) | 38.9% |
| Worst drawdown (1 year) | -28.7% |
| Average daily value traded | 24.27M EUR |
| Dividend yield | 0.2% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Bayer is a life sciences company based in Germany. It develops and makes prescription medicines, over-the-counter health products and crop protection products for farmers. Its pharmaceutical business supplies treatments in areas such as cardiology, oncology and women's health, while its consumer health arm offers familiar remedies for pain, colds and everyday ailments. The agricultural side provides seeds, herbicides and other products for crop growers. Bayer serves hospitals, doctors, pharmacies, retailers and farming customers around the world.
The shares are listed on the London Exchange in UK under the code 0P6S, and the price on this page is in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Bayer AG NA (0P6S) trades on the London Exchange in UK. It last closed at EUR 44.77 on 21 October 2026.
Its price-based Market X-Ray is 60 out of 100 (a fair price profile), ranking 1,288 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 67.4% and over the last three months it fell 3.2%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 63 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 3.4% | ||
| From 52-week high | -15.7% | ||
| Momentum | 68 · Fair | Typical recent returns for this exchange. | |
| 3-month return | -3.2% | ||
| 6-month return | 11.0% | ||
| 12-month return, skipping the last month | 84.8% | ||
| Stability (higher is calmer) | 47 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 38.9% | ||
| Worst drawdown, 1 year (smaller is calmer) | -28.7% | ||
| Liquidity | 80 · Strong | Trades actively. | |
| Average daily value traded | 24.27M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 39 · Weak | Dividend is small or irregular. | |
| Dividend yield | 0.2% | ||
| Years with dividends | 5 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Income: Dividend is small or irregular.
Returns
| 1 week | −0.7% |
|---|---|
| 1 month | −9.4% |
| 3 months | −3.2% |
| 6 months | +11.0% |
| 1 year | +67.4% |
| 3 years | +4.2% |
| 5 years | – |
Signals
| 50-day / 200-day average | 47.42 / 43.28 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.21 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 27 Apr 2026 | EUR 0.1100 |
| 28 Apr 2025 | EUR 0.1100 |
| 29 Apr 2024 | EUR 0.1100 |
| 1 May 2023 | EUR 2.4000 |
| 2 May 2022 | EUR 2.0000 |
| 28 Apr 2021 | EUR 2.0000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.